secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K/A
Filed at:   2022-08-24T23:59:59+00:00
Accession:  0000950103-22-014407
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen completes $170M sale of Trans Ova Genetics; pro forma shows $213M cash
-------------------------------------------------------------------------------

- Closed sale of 100% of Trans Ova to Spring Bidco LLC for $170M; net cash proceeds ~$169.5M.
- Pro forma cash and equivalents rise to $213.4M from $43.8M as of June 30, 2022.
- Pro forma continuing ops loss of $49.2M for H1 2022 vs. historical loss of $36.9M (net of discontinued ops).
- Pro forma continuing ops loss of $110.8M for FY2021, compared to historical net loss of $96.8M.
- Pro forma balance sheet eliminates $88.9M of assets and $15.1M of liabilities classified as held for sale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010322014407/0000950103-22-014407-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010322014407/dp178970_8ka.htm
  HTML page:      https://secwatch.observer/filing/0000950103-22-014407

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer